SavedAdd your journal

Journals / Pharmata / 2022 / Cilt: 2 Sayı: 3

Chemical Structure and Synthesis of Baloxavir Marboxil, A Novel Endonuclease Inhibitor For The Treatment Influenza : An Overview

Amine Sena AYDIN
Halise İnci GÜL
Journal
Pharmata
Pages
91–99
Publication Date
2022-07-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, we summarized the chemical structure, synthesis, mechanism of action, pharmacological activity and synthesis of Baloxavir marboxil, a novel FDA-approved endonuclease inhibitor for the treatment of influenza.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:One drug target that was identifed as a promising candidate for infuenza antiviral drugs is the infuenza virus polymerase complex.
📊
Key Findings & Data:The three-component polymerase complex, which is highly conserved and is essential for infuenza virus replication, has received considerable attention as a potential target for infuenza antiviral drugs.
💡
Conclusion & Impact:In this review, we summarized the chemical structure, synthesis, mechanism of action, pharmacological activity and synthesis of Baloxavir marboxil, a novel FDA-approved endonuclease inhibitor for the treatment of influenza.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Antiviral · baloxavir marboxil · endonuclease inhibitor

Abstract

One drug target that was identifed as a promising candidate for infuenza antiviral drugs is the infuenza virus polymerase complex. The three-component polymerase complex, which is highly conserved and is essential for infuenza virus replication, has received considerable attention as a potential target for infuenza antiviral drugs. Baloxavir marboxil (Xofuza®; hereafter referred to as baloxavir), the prodrug of baloxavir acid, is a frst-in-class, small molecule inhibitor of the cap-dependent endonuclease reaction that is conducted by the polymerase acidic (PA) protein subunit of the infuenza virus polymerase complex. In this review, we summarized the chemical structure, synthesis, mechanism of action, pharmacological activity and synthesis of Baloxavir marboxil, a novel FDA-approved endonuclease inhibitor for the treatment of influenza.

🔖

Cite This Article

AYDIN, A. S., GÜL, H. İ. (2022). Chemical Structure and Synthesis of Baloxavir Marboxil, A Novel Endonuclease Inhibitor For The Treatment Influenza : An Overview. Pharmata, Cilt: 2 Sayı: 3, 91–99. https://ajindex.com/articles/947933

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Thompson, W.W., et al., Estimates of US influenza‐associated deaths made using four different methods. Influenza and other respiratory viruses, 2009. 3(1): p. 37-49
  2. Falgout, B., R. Miller, and C.-J. Lai, Deletion analysis of dengue virus type 4 nonstructural protein NS2B: identification of a domain required for NS2B-NS3 protease activity. Journal of virology, 1993. 67(4): p. 2034-2042
  3. Dong, G., et al., Adamantane-resistant influenza a viruses in the world (1902–2013): frequency and distribution of M2 gene mutations. PloS one, 2015. 10(3): p. e0119115
  4. Treanor, J.J., et al., Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. Jama, 2000. 283(8): p. 1016-1024
  5. Nicholson, K., et al., Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. The Lancet, 2000. 355(9218): p. 1845-1850
  6. Lee, N., et al., Viral loads and duration of viral shedding in adult patients hospitalized with influenza. The Journal of infectious diseases, 2009. 200(4): p. 492-500
  7. Belongia, E.A., et al., Clinical characteristics and 30-day outcomes for influenza A 2009 (H1N1), 2008-2009 (H1N1), and 2007-2008 (H3N2) infections. Jama, 2010. 304(10): p. 1091-1098
  8. Hughes, D.L., Review of the patent literature: synthesis and final forms of antiviral drugs tecovirimat and baloxavir marboxil. Organic Process Research & Development, 2019. 23(7): p. 1298-1307
  9. FDA Review. [cited 2022 25 May]; Available from:
  10. Ng, K.E., Xofluza (Baloxavir Marboxil) for the treatment of acute uncomplicated influenza. Pharmacy and Therapeutics, 2019. 44(1): p. 9
  11. Ando, Y., et al., Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection. Journal of Antimicrobial Chemotherapy, 2021. 76(1): p. 189-198
  12. Dufrasne, F., Baloxavir marboxil: An original new drug against influenza. Pharmaceuticals, 2021. 15(1): p. 28
  13. Yang, T., Baloxavir marboxil: the first cap-dependent endonuclease inhibitor for the treatment of influenza. Annals of Pharmacotherapy, 2019. 53(7): p. 754-759
  14. Louten, J., Virus replication. Essential human virology, 2016: p. 49
  15. Jackson, D., R.A. Elderfield, and W.S. Barclay, Molecular studies of influenza B virus in the reverse genetics era. Journal of General Vir